Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients

Table 3 Univariate and multivariate analysis (Cox regression) of factors associated with overall survival in 399 consecutive patients with metastatic colorectal cancer

		Univariate analysisn= 399				Multivariate analysisn= 214
		HR	95%CI		P	HR	95%CI		P
Age					< 10-4
	≥ 75	1.77	1.33	2.35
Sex					0.615
	Male	1
	Female	1.06	0.85	1.33
Origin					0.04				0.0767
	Colon	1				1
	Rectum	0.75	0.57	0.99		0.68	0.44	1.04
WHO PS					< 10-4				0.021
	0	1				1
	1-2-3-4	2.15	1.63	2.82		1.53	1.07	2.19
CEA					< 10-4				0.143
	< 200	1				1
	≥ 200	2.31	1.72	3.09		1.37	0.90	2.09
Prior anemia					< 10-4				0.188
	No	1				1
	Yes	1.83	1.45	2.31		0.79	0.55	1.13
Anemia					0.005				0.029
	No	1				1
	Yes	1.91	1.22	2.98		2.19	1.08	4.41
Thrombopenia					0.003				0.036
	No	1				1
	Yes	0.70	0.56	0.88		0.69	0.49	0.98
Neutropenia					< 10-4				< 10-4
	No	1				1
	Yes	0.55	0.44	0.705		0.43	0.29	0.64
Metastatic sites					0.005				0.026
	1	1				1
	> 1	1.40	1.11	1.77		1.49	1.05	2.11
Surgery of the primary tumor					< 10-4				< 10-3
	No	1				1
	Yes	0.33	0.25	0.44		0.46	0.30	0.70
Surgery of metastatic site					< 10-4				< 10-3
	No	1				1
	Yes	0.27	0.21	0.36		0.48	0.31	0.74
ALP					< 10-4				0.007
	< 300	1				1
	≥ 300	3	2.16	4.18		1.81	1.18	2.78
LDH					< 10-4				< 10-3
	< 233	1				1
	≥ 233	2.15	1.62	2.85		2.03	1.38	2.97
Leucocyte count					< 10-4
	< 10000	1
	≥ 10000	2.04	1.53	2.73
Anti-EGFR Mab					0.006
	No	1
	Yes	0.73	0.58	0.91
Bevacizumab					< 10-4				0.107
	No	1				1
	Yes	0.61	0.49	0.76		0.76	0.55	1.06
Chemotherapy lines					< 10-4
	< 2	1
	≥ 2	0.46	0.32	0.66
Chemotherapy molecules					< 10-4
	1	1
	2	0.5	0.29	0.87
	3	0.35	0.21	0.58

WHO PS: WHO performance status; ALP: Alkaline phosphatase; LDH: Lactate dehydrogenase.